In the UK a single national appraisal decides commissioning, and the route it takes — standard appraisal or the ultra-rare pathway — sets the cost-effectiveness bar an asset must clear.
NICE is the gate. A positive technology appraisal triggers a mandatory funding obligation in England, so a recommendation converts to commissioned access in a way few other markets match. A rejection leaves an asset without a route, whatever the licence says.
Which pathway an appraisal takes matters more than most launch plans assume. The standard Technology Appraisal route applies an ordinary cost-per-QALY threshold; the Highly Specialised Technologies route applies a far higher one, but admits very few medicines. Assuming the ultra-rare route and being assessed on the standard one is the single most expensive planning error in UK rare disease, and the AXLRx corpus documents several therapy areas where every incumbent cleared the standard bar — setting a precedent a new entrant inherits whether or not it wants to.
Almost every recommendation is underpinned by a confidential commercial arrangement, so published list prices reveal little about what the NHS actually pays. Scotland and Wales assess separately, and can and do diverge.
AXLRx UK reports work that structure directly: which route an asset should expect, the precedent set by agents already through, the discount implied to clear the threshold, and the evidence a submission has to be built on from the first dossier decision.
Tafamidis's ATTR-CM franchise meets acoramidis under NICE — which now tells clinicians to pick the least-expensive stabiliser.
IgAN doesn't qualify for the ultra-rare HST track, so both novel agents must clear the standard £20,000-30,000/QALY bar. Both sit in Named Patient access ahead of their NICE decisions.
The UK Pompe Consortium registry counts roughly 200 confirmed patients. Total estimated prevalence, including the undiagnosed pool, runs 350-450. Within the confirmed, treated population, 30-50 are ADA-positive inadequate responders and 80-120 are on home ventilation.
NICE's terminated eculizumab appraisal for gMG remains the price precedent every new asset must clear. 2,000-3,000 refractory patients have no NICE-commissioned biologic option, and the IVIg-offset economics decide whether a launch is viable.
A 37-centre national survey confirms 1,152 UK HAE type I/II patients. A top-down 1:32,000 prevalence rate implies roughly 2,000, and the UK HAE Alliance's broader planning estimate runs to 5,000-6,000, of which only 1,500-2,000 are on prophylaxis today.
The UK SMA population is not one number. A ~1,000-patient actively-monitored NHS cohort and a 1,800-2,000-patient total prevalence estimate both appear across UK sources, and the gap between them is the pre-NBS legacy population outside the four specialist networks' active census.
An ADA-positive-specific NICE case beats competing on incremental FVC improvement against alglucosidase. The 80-120 NIV-dependent LOPD patients are the highest-urgency target, and the BIMDG partnership shapes NICE's evidence bar.
The £144M NHS Fabry market is the largest in Europe, and already has two established agents. An ADA-positive or female-heterozygote niche, not general ERT improvement, is the only viable UK entry point.
Pegunigalsidase's suboptimal-responder recommendation (TA915) reshapes NHS-commissioned Fabry therapy. It sets oral migalastat against IV enzyme replacement across the UK treated population.
NICE's accepted cost-effectiveness case for budesonide (TA937, updated by TA1128) rests on a 5–8 year modelled ESRD delay. The same mandatory ACEi/ARB gate applied to sparsentan narrows the UK's eligible IgA nephropathy population from 10,000–15,000 to 3,000–5,000 patients.
Crizanlizumab's EMA/MHRA withdrawal leaves a VOC-prevention gap. Casgevy's NICE recommendation is the watershed NHS gene-therapy access event — Lyfgenia has no UK regulatory status.
The UK ran Europe's first national SMA newborn-screening programme. All three therapies are NICE-recommended with commercial arrangements, across a living UK cohort of ~1,000 patients in four disease types.
Newborn screening has been universal since 1999, so the UK's 15,000-17,000 diagnosed sickle cell patients are counted with confidence. They narrow to a 4,000-6,000-patient conventional-therapy gap and a separate 200-300-per-year gene-therapy-eligible pool.
UK HAE Alliance genetic testing, an 87% attack-rate reduction on lanadelumab, and the NICE TA606 prophylaxis standard defining NHS management.
700-900 NHS-diagnosed Fabry patients split cleanly by therapy. Roughly 600 are on enzyme replacement and about 200, or 25%, on oral migalastat, with free NHS cascade testing adding 3-4 diagnosed relatives per index case.
Leeds National Registry data, FLAER access without referral, and the 30% PNH-aplasia overlap defining the NHS commercial picture.
A single five-centre South West England consortium tracks 666 UK patients across all three approved CDK4/6 inhibitors. That kind of coordinated, multi-centre evidence generation is exactly the institutional signal this workbook sizes before any individual name enters it.
NICE will reject any IgAN submission not built on eGFR slope with mandatory SGLT2i background. This sizes the 3,000-5,000 UK patients eligible for a novel agent and the ESRD-delay cost model that clears the QALY bar.
A ~25% inadequate-ERT-responder subset defines the next-generation enzyme-replacement opportunity in UK Pompe. The UK Pompe Consortium's shared-care network sits against a 3–8 year late-onset diagnostic delay.
Both ravulizumab and iptacopan cleared NICE's standard Technology Appraisal route (TA698 and TA1000). The real payer question is how fast the NHS converts patients from IV ravulizumab to oral iptacopan, not which drug got the easier appraisal at the ordinary £20,000–£30,000/QALY bar.
NICE accepts palbociclib, ribociclib, and abemaciclib as comparators for each other. No trial has ever tested any of them head-to-head against exemestane plus everolimus, the older endocrine-based comparator regimen they effectively replaced.
True UK ATTRwt-CM prevalence runs 20,000-40,000, and 15,000-36,000 of those patients remain undiagnosed. Only 3,000-4,000 are on NHS-commissioned tafamidis today, adding 1,500-2,000 a year.
England's NICE has issued three positive technology appraisals funding HAE prophylaxis since 2019 (TA606, TA738, TA1101). The two newest MHRA-licensed agents, donidalorsen and sebetralstat, remain in NICE appraisal with no confirmed final NHS funding decision.
All three funded SMA therapies in England reached the NHS through a conditional route. Zolgensma was recommended under HST15 and extended under HST24; nusinersen and risdiplam spent seven years in managed access before TA1162 moved them to routine commissioning.
NICE recommended both Dravet therapies through standard Technology Appraisal, not the ultra-rare HST route. This covers what the Fintepla Cardiac Monitoring Scheme costs the NHS, and why the UK treatment algorithm is now closed to new entrants without a significant clinical edge.
NICE TA696, since updated by TA984, opened NHS commissioning of tafamidis for ATTR-CM at scale. Acoramidis's pending appraisal and vutrisiran's TA868 access route are the two other decisions defining the UK amyloidosis market.
~600-750 UK PNH patients are on active complement-inhibitor therapy against a reconciled total prevalence near 1,500. The other 750-900 are monitored-only or undiagnosed, and this model sizes the gap.
350-450 UK Pompe disease patients, of whom roughly 200 form the registry-confirmed cohort. One in four long-term ERT patients is not holding stable, the segment this model is built to size.
NICE has cleared every modern PNH anti-complement therapy through the standard £20,000-30,000 Technology Appraisal route. From ravulizumab to crovalimab, none used the more generous Highly Specialised Technologies threshold, and each went via a confidential patient access scheme.
A ~4,000-patient UK gMG treatment gap remains unresolved. Efgartigimod's June 2025 NICE rejection (TA1069) left it open, against NHS neuromuscular network diagnostics.
Vutrisiran's TA868 PAS-backed approval is reshaping UK ATTR identification and treatment. It joins NICE-commissioned tafamidis access (TA696, updated by TA984) and a 30-centre Tc-PYP diagnostic pathway.
NHS England's Pompe commissioning policy defines a 45-50 patient switch-eligible cohort for avalglucosidase alfa (NICE TA821). That is a manageable NHS budget event; broader first-line uptake would be a materially larger one.
The National Amyloidosis Centre holds the clinical-expert seat at every NICE ATTR appraisal to date. This workbook sizes the UK ATTR KOL network before a name enters it: NAC's 400-500-patient ATTRv surveillance registry, the separate UCL and Queen Elizabeth Hospital Birmingham National ATTRv Registry tracking approximately 800 patients, and the roughly 30 NHS centres running Tc-PYP scintigraphy nationally.
Migalastat's HST4 recommendation in 2016 was the first oral mutation-specific rare disease therapy NICE approved. Agalsidase beta was never formally appraised at all. Together they underpin an estimated £144M NHS Fabry programme, with a £70-130K/patient/year switch incentive still unrealised at scale.
Four London teaching hospitals anchor roughly 6,000 of the UK's 15,000-17,000 sickle cell patients. Barts, King's, Imperial and Homerton, with Birmingham Heartlands, Manchester, Bristol and Nottingham forming the next ring. That eight-centre structure is exactly the institutional signal this workbook sizes before any individual name enters it.
Four NHS Highly Specialised Services networks and six designated gene-therapy centres carry the UK SMA treatment pathway. This workbook sizes that institutional structure, plus the Bristol Institute of Child Health attenuation-cohort follow-up, before any physician name enters it.
NICE's SCD gene therapy appraisal may be the largest NHS rare disease budget event in history. It hinges on an annuity payment model that current NHS SCD management cost cannot yet clearly justify.
Agalsidase beta runs an estimated £150-250K per patient per year against migalastat's £80-120K. NICE has quantified that £70-130K annual switch saving but the NHS has not captured it at scale, and pegunigalsidase's TA915 commercial arrangement now sets a third price point.
NICE's accepted 20-35% PAS discount off budesonide's WAC sets the pricing floor sparsentan already clears. The £140-180M NHS budget ceiling applies once the ACEi/ARB gate narrows eligibility to 3,000-5,000 patients.
NICE has never modelled a cost-per-QALY for a myasthenia gravis biologic. Eculizumab's appraisal (TA636) closed before a dossier was submitted; efgartigimod's (TA1069) closed on evidence gaps, not a quantified ICER breach. A new entrant inherits no reusable comparator or price benchmark from either.
Both existing Dravet therapies cleared NICE's standard Technology Appraisal, not the ultra-rare Highly Specialised Technology route. A new entrant's WAC, PAS, and stakeholder-engagement calendar all need to be built against that lower cost-effectiveness bar, with soticlestat's 2026-27 appraisal setting the clock.
UK Renal Registry data, the ACEi/ARB-first Renal Association pathway, and the NHS economic case for novel agents built on £40–50M annual ESRD cost.
NICE recommended crizanlizumab in 2021, then withdrew the guidance in 2023 when the confirmatory trial failed. The licence was revoked. In UK sickle cell, price is not the binding constraint. Confirmatory evidence is.
Near-universal newborn screening puts the UK's 15,000-17,000 SCD patients on the registry with confidence. But only the 4,000-6,000 hydroxycarbamide-inadequate subset is the addressable population for a new non-gene agent.
All three SMA therapies cleared NICE with confidential PAS. The UK's 2021 newborn screening programme is now the real access lever, shifting competition to physician and family preference.
600-900 UK Dravet patients remain uncontrolled on CBD plus fenfluramine. This weighs the cardiac-monitoring burden a REMS-free agent could remove against the soticlestat clock competing for the same refractory population.
A mature three-drug NICE framework leaves no room for parity entry in UK SMA. The Zolgensma-attenuation and Type 4 adult niches are unserved, and NHS gene therapy centre capacity constrains every new entrant.
NICE's June 2025 rejection of efgartigimod (TA1069) leaves UK myasthenia gravis with no NICE-recommended novel agent. Eculizumab's own appraisal (TA636) was withdrawn by the manufacturer in 2020 without a cost-effectiveness verdict, and the NHS IVIg cost-offset argument is now the strongest lever for a future resubmission.
The broader estimate puts 12,000-15,000 UK patients with generalised myasthenia gravis. About 4,000 have moderate-severe disease and 2,000-3,000 are refractory, with no NICE-recommended novel agent for any of them.
Any new ATTR-CM entrant is judged against tafamidis on NICE's TA984 QALY bar, now joined by acoramidis's TA1121 recommendation. The diagnosis pipeline still leaves 15,000-36,000 UK patients undiagnosed, and the National Amyloidosis Centre is the single investment that decides the outcome.
2,000-2,500 UK Dravet patients, of whom 400-500 are SCN1A-confirmed in genetic registries. 600-900 remain inadequately controlled on cannabidiol plus fenfluramine.
The UK has Europe's largest SCD population at 15,000–17,000 patients. Newborn screening has made diagnosis near-universal since 1999, and NICE's recommendation of Casgevy (TA1044) will define UK access to a functional cure.
A ~1,000-patient confirmed UK SMA cohort by type reconciles against a 1,800-2,000-patient total prevalence estimate. A 50-60/yr Zolgensma cohort is the on-therapy validation anchor.
NICE TA606 commissioned lanadelumab with a PAS and 87.5% real-world attack reduction. Berotralstat's TA738 recommendation is now tested against that same benchmark.
All three UK PNH agents cleared NICE via the standard Technology Appraisal route, not the ultra-rare one. Ravulizumab (TA698), iptacopan (TA1000) and crovalimab all took it. Convenience and switch dynamics, not pathway-driven affordability, now determine NHS share.
Fewer than 25 consultants manage over 90% of the UK's PNH caseload. They sit across five NHS Highly Specialised Services centres anchored by the Leeds National PNH Service. That kind of institutional concentration is exactly the signal this workbook sizes before any individual name enters it.
Ultomiris cannot resolve the EVH-dominant PNH population, and that gap defines the UK opportunity. Every PNH agent has now cleared the standard NICE Technology Appraisal bar; this sizes the PAS discount required to hit it before MHRA approval.
NICE accepts a £100,000-300,000 QALY threshold for ultra-rare Pompe disease, five to fifteen times the standard appraisal bar. That Highly Specialised Technologies ceiling is what avalglucosidase alfa's TA821 recommendation used, but only with a substantial confidential commercial arrangement. A new entrant without that leverage should build a standalone case for the antibody-positive inadequate-responder subgroup instead.
The UK's NICE-commissioned Dravet algorithm manages an estimated 2,000-2,500 patients on cannabidiol and fenfluramine. The NHS genetic testing registry logs only 400-500 molecularly SCN1A-confirmed cases — a registry-scope gap, not a population contradiction.
NICE recommends both ATTR-CM stabilisers, tafamidis (TA984) and acoramidis (TA1121), and directs clinicians to the cheaper one. Acoramidis cleared on indirect comparison alone. A third entrant must beat an invisible, PAS-discounted floor, with no published price target.
10,000-15,000 UK IgA nephropathy patients, of whom approximately 8,000 are tracked in the UK Renal Registry. Only 3,000-5,000 clear the mandatory ACEi/ARB and SGLT2i optimisation gate to become eligible for a novel agent, and fewer than 500 currently access one pre-NICE.
Two UK gMG estimates disagree by 3-4x on purpose. A narrower moderate-severe subgroup of roughly 4,000 from the MGA UK survey sits inside a broader 12,000-15,000 total prevalence figure that also counts mild, well-controlled cases the narrower estimate excludes.
The NHS runs the most treatment-advanced Dravet pathway in Europe. Free SCN1A testing on GMS, a NICE-defined CBD-then-fenfluramine algorithm, and 25 paediatric epilepsy HSS centres underpin it.
An estimated 800-patient UK Fabry cohort has both NHS-commissioned ERT and NICE HST4-recommended oral chaperone therapy. The NHS lysosomal-storage-disorder specialist network and UK Fabry Outcome Survey longitudinal data track it.
The Leeds National PNH Registry tracks about 600 UK patients on complement-inhibitor therapy. A broader estimate cited in AXLRx's own Launch Readiness research puts it near 1,500 total patients and 1,000 treated. Reconciling which count anchors a sizing model is the open question.
NICE built UK SMA access in sequence, not as an open field. Gene therapy took the pre-symptomatic subgroup first (HST15, HST24), then TA1162 moved chronic therapy to routine funding behind it. A new entrant inherits a fixed subgroup hierarchy and a comparator that shifts by population.
NICE recommended crizanlizumab (TA743) via managed access in 2021, then withdrew it in 2023 after the confirmatory trial failed. Casgevy (TA1044) cleared only by restructuring its £1.65M price into managed access. A new entrant inherits no reusable ICER benchmark from either.
Three completed NICE standard technology appraisals already fund HAE prophylaxis in England (TA606, TA738, TA1101). Every one cleared at the ordinary £20,000 to £30,000 per QALY bar and is held behind a confidential Patient Access Scheme, so a new entrant inherits a comparator-dense field in which garadacimab's £20,625 list pen is the only transparent price.
NICE accepted an eGFR-slope-to-ESRD-delay model, not headline proteinuria reduction, as the value basis in IgA nephropathy. That covers budesonide (TA937, expanded by TA1128) and sparsentan (TA1074). The mandatory ACEi/ARB and SGLT2 inhibitor optimisation gate narrows the UK's 10,000 to 15,000 patients to a 3,000 to 5,000 novel-agent-eligible pool before that pricing math applies.
NICE's rejection of crizanlizumab on price alone is the binding constraint for any new SCD agent. 4,000-6,000 UK patients sit in a post-withdrawal white space, and the WAC ceiling decides whether you repeat that outcome.
Six NHS centres concentrate the UK's refractory Dravet syndrome cohort. Great Ormond Street, Bristol, Alder Hey, Birmingham Children's, Leeds and Newcastle. The British Paediatric Neurology Association's Dravet working group shapes NICE evidence review 18-24 months ahead of submission, and that institutional network is what this workbook sizes first, not a roster of named physicians.
A six-physician BIMDG subcommittee advises NICE directly on Pompe disease. It sits at the centre of a five-centre UK Pompe Consortium and an eight-centre NHS Highly Specialised Service network. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it.
Both NHS-commissioned Dravet therapies cleared NICE's standard £20,000-30,000/QALY bar, not the ultra-rare HST threshold. A new entrant is held to the same bar the incumbents already cleared, and total NHS Dravet spend still runs a modest £9-16M.
The UK Renal Registry tracks about 8,000 IgA nephropathy patients against an estimated 10,000-15,000 total prevalence. Only 3,000-5,000 are eligible for a novel agent, and fewer than 500 currently receive one.
The Renal Association's IgAN guideline committee, not any single physician, sets the reference point NICE checks against. This workbook sizes that committee and the network behind it before individual outreach begins.
700-900 diagnosed UK Fabry patients split roughly 600 on ERT to 200 on oral therapy. Two niches sit inside that: 50-80 ADA-positive suboptimal responders and 80-120 undertreated symptomatic female heterozygotes, against a £144M NHS spend anchor.
NICE's TA1121 cost-minimisation rule directs clinicians to whichever ATTR-CM stabiliser costs less. That rule, not the QALY threshold alone, now sets a new entrant's UK price ceiling.
The UK HAE Alliance counts 5,000-6,000 total patients, of whom 1,500-2,000 are on NICE-commissioned prophylaxis. A further 1,500-2,500 are attack-active but never treated, and Longhurst et al.'s 37-centre registry confirms 1,152 patients from the bottom up.
UK Fabry disease is commissioned through three different NICE and NHS routes at once. No formal technology appraisal for either enzyme replacement therapy, a Highly Specialised Technologies recommendation (HST4, 2016) for migalastat, and a standard appraisal (TA915, 2023) for pegunigalsidase alfa. A new entrant inherits no single reusable comparator or price benchmark.
NICE has cleared all four modern PNH anti-complement therapies through its standard £20,000-30,000 Technology Appraisal route. Ravulizumab TA698, pegcetacoplan TA778, iptacopan TA1000 and crovalimab TA1019, each contingent on a confidential commercial arrangement, never the Highly Specialised Technologies threshold. A new submission inherits an unbroken standard-STA precedent it must be built to clear from the first dossier decision.
NHS-commissioned alglucosidase alfa runs £200,000-350,000 per patient a year post-PAS. Avalglucosidase alfa's NICE TA821 recommendation carries a 20-30% WAC premium and a switch-population budget impact of just £2-4M a year.
No UK gMG biologic has ever cleared NICE at any price. Eculizumab's manufacturer withdrew before submitting an ICER, and efgartigimod's June 2025 rejection means a future entrant's price ladder starts from zero precedent, not a benchmark.
No novel biologic is yet NHS-commissioned for generalised MG. Eculizumab's manufacturer withdrew its 2020 NICE appraisal before a verdict, and NICE rejected efgartigimod outright in 2025 — leaving rozanolixizumab as the FcRn class's last untested NICE bid.
Five NHS specialist centres manage more than 90% of UK HAE patients. Sheffield, Cambridge, Birmingham, Guy's and St Thomas', and Manchester. That concentration is what this workbook sizes before any physician enters the K1-K6 gate structure.
Royal Free London's National Fabry Service was NICE's appointed clinical expert twice over. It advised on both migalastat's HST4 and pegunigalsidase alfa's TA915, across a network of five named NHS lysosomal storage disorder centres. That repeated appointment is exactly the institutional signal this workbook sizes before any individual name enters it.
A 30-centre NHS neuromuscular network coordinated through Muscular Dystrophy UK carries UK myasthenia care. That network, plus a 3,000-member Myasthenia Gravis Association UK patient registry, is the institutional signal this workbook sizes before any individual name enters it.
National Amyloidosis Centre-anchored epidemiology puts UK ATTRwt-CM prevalence at 20,000-40,000. Only 3,000-4,000 patients are on NICE-commissioned tafamidis today, leaving 15,000-36,000 undiagnosed.
Avalglucosidase alfa's NICE recommendation (TA821) puts it against entrenched alglucosidase alfa. NHS switch criteria and the Pombiliti queue position define the next 18 months of UK access.
Cannabidiol and fenfluramine anchor the NHS-commissioned NICE algorithm; stiripentol still holds a backbone role. New entrants must beat an entrenched three-drug sequence, not just show efficacy.
Every SMA therapy the NHS funds entered through a conditional route. Nusinersen and risdiplam sat in time-limited managed access from 2019 until TA1162 moved them to routine commissioning. UK SMA pricing is a question of how long an asset stays conditional.
Three NICE technology appraisals (TA606, TA738, TA1101) each carry a confidential Patient Access Scheme. Garadacimab's published £20,625 per-pen price is the only fully transparent figure in the class, and two MHRA-licensed agents still have no NICE-confirmed net price.
Lanadelumab leaves the never-prophylaxed UK HAE population open. This sizes the PAS discount needed to clear NICE's standard TA bar, and the donidalorsen clock a fast-moving competitor is running against you.